In February 2021, Moderna announced that “no serious adverse effects were observed” in an article about the preliminary results of the mRNA vaccine trial published in the medical journal Vaccine.
Moderna was halfway through phase 2 of its P201 vaccine trial that enlisted 600 participants. Phase 2 vaccine testing aimed to further determine vaccine safety, document short-term side effects, and observe immune system responses to the vaccine.
Of the 600 considered healthy volunteers, 200 received the 100-microgram dose that became the approved version, 200 received a lower dose, and 200 received a placebo. Two variants of the vaccine were tested in the trial.
The company had good news. The “highlights” section at the top of the paper announced that no serious adverse effects (SAE) had occurred during the P201 trial….